Plasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy
Open Access
- 14 October 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e015873
Abstract
Predicting sustained clinical benefit from immunochemotherapy in advanced non-small cell lung cancer (NSCLC) remains a major challenge. This study aimed to identify plasma cell-free RNA (cfRNA) biomarkers for predicting long-term progression-free survival (PFS ≥24 months). Extracellular vesicle-enriched cfRNA sequencing was performed on 165 patients with advanced NSCLC (discovery cohort, n=82; prospective validation cohort, n=83) and 50 healthy controls. A multistep screening approach, including differential expression and Cox regression analyses, was used to identify candidate biomarkers, which were further validated by reverse-transcription quantitative PCR. ITGB3 was identified as the most robust prognostic biomarker. Low baseline ITGB3 expression was significantly associated with superior survival outcomes. In the discovery cohort, the median PFS was 25.8 months for the ITGB3-low group versus 8.4 months for the ITGB3-high group (HR 0.325, pITGB3 demonstrated high prognostic accuracy with areas under the curve (AUCs) of 0.760 and 0.796 in the discovery and validation cohorts, respectively. Combining ITGB3 with three-level programmed death-ligand 1 (PD-L1) status yielded an AUC of 0.812, suggesting that the two biomarkers may provide complementary prognostic information. Multivariable analysis confirmed baseline ITGB3 as an independent prognostic factor for both PFS (HR=1.27, pITGB3 is a robust, non-invasive biomarker for identifying patients likely to achieve long-term benefit from immunochemotherapy, providing complementary value to traditional PD-L1 assessment.Keywords
Funding Information
- National Natural Science Foundation of China (No. 82272625)
- National Science and Technology Major Project (No. 2026ZD0557403)
- Science and Technology Commission of Shanghai Municipality (No. 22Y31920405)
- Shanghai Municipal Health Commission (No. 2020CXJQ02)
This publication has 50 references indexed in Scilit:
- Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophagesCancer Communications, 2025
- The impact of POSTN on tumor cell behavior and the tumor microenvironment in lung adenocarcinomaInternational Immunopharmacology, 2024
- Exosomal CTHRC1 from cancer-associated fibroblasts facilitates endometrial cancer progression via ITGB3/FAK signaling pathwayHeliyon, 2024
- Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology CommitteeJournal of Thoracic Oncology, 2020
- EV-origin: Enumerating the tissue-cellular origin of circulating extracellular vesicles using exLR profileComputational and Structural Biotechnology Journal, 2020
- Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic ResistanceCancer Cell, 2019
- Large Differences in Small RNA Composition Between Human BiofluidsCell Reports, 2018
- Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of GlioblastomaCancer Cell, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009